Bio Green Med Solution, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Bio Green Med Solution, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $0 | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $43.0K | Mar 30, 2026 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $0 | Mar 30, 2018 |
| FY2017 | Dec 31, 2016 | $843.0K | Mar 30, 2018 |
| FY2016 | Dec 31, 2015 | $1.94M | Mar 31, 2017 |
| FY2015 | Dec 31, 2014 | $1.73M | Mar 29, 2016 |
| FY2014 | Dec 31, 2013 | $1.08M | Mar 31, 2015 |
| FY2013 | Dec 31, 2012 | $69.0K | Mar 26, 2014 |
| FY2011 | Dec 31, 2011 | $699.0K | Mar 30, 2012 |
| FY2012 | Dec 31, 2010 | $112.0K | Apr 1, 2013 |
| FY2011 | Dec 31, 2009 | $911.0K | Mar 30, 2012 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($3.00M) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($11.21M) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | ($22.56M) | Nov 26, 2025 |
| FY2023 | Dec 31, 2022 | ($21.20M) | Mar 21, 2024 |
| FY2022 | Sep 30, 2022 | ($5.10M) | Nov 29, 2023 |
| FY2022 | Jun 30, 2022 | ($4.58M) | Nov 29, 2023 |
| FY2022 | Dec 31, 2021 | ($18.46M) | Nov 29, 2023 |
| FY2022 | Sep 30, 2021 | ($4.76M) | Nov 29, 2023 |
| FY2021 | Dec 31, 2020 | ($8.45M) | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | ($7.83M) | Mar 1, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($8.43M) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($12.00M) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | ($25.45M) | Nov 26, 2025 |
| FY2023 | Dec 31, 2022 | ($27.66M) | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | ($22.39M) | Nov 29, 2023 |
| FY2022 | Sep 30, 2021 | ($5.70M) | Nov 29, 2023 |
| FY2021 | Dec 31, 2020 | ($10.64M) | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | ($9.68M) | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | ($9.55M) | Mar 5, 2020 |
| FY2018 | Dec 31, 2017 | ($9.49M) | Mar 28, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $848.0K | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $6.66M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $19.16M | Nov 26, 2025 |
| FY2023 | Dec 31, 2022 | $20.27M | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | $14.93M | Nov 29, 2023 |
| FY2022 | Sep 30, 2021 | $3.92M | Nov 29, 2023 |
| FY2021 | Dec 31, 2020 | $4.76M | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | $4.66M | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | $4.33M | Mar 5, 2020 |
| FY2018 | Dec 31, 2017 | $4.24M | Mar 28, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $5.39M | Apr 2, 2025 |
| FY2024 | Dec 31, 2023 | $6.72M | Apr 2, 2025 |
| FY2023 | Dec 31, 2022 | $7.38M | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | $7.46M | Nov 29, 2023 |
| FY2021 | Dec 31, 2020 | $5.88M | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | $5.02M | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | $5.37M | Mar 5, 2020 |
| FY2018 | Dec 31, 2017 | $5.25M | Mar 28, 2019 |
| FY2017 | Dec 31, 2016 | $5.52M | Mar 30, 2018 |
| FY2016 | Dec 31, 2015 | $5.73M | Mar 31, 2017 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($4.77M) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($7.99M) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | ($16.11M) | Nov 26, 2025 |
| FY2023 | Dec 31, 2022 | ($20.83M) | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | ($18.54M) | Nov 29, 2023 |
| FY2021 | Dec 31, 2020 | ($7.93M) | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | ($9.45M) | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | ($6.70M) | Mar 5, 2020 |
| FY2018 | Dec 31, 2017 | ($7.48M) | Mar 28, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2023 | $6.0K | Nov 26, 2025 |
| FY2023 | Dec 31, 2022 | $7.0K | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | $27.0K | Nov 29, 2023 |
| FY2021 | Dec 31, 2020 | $96.0K | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | $10.0K | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | $39.0K | Mar 5, 2020 |
| FY2018 | Dec 31, 2017 | $13.0K | Mar 28, 2019 |
| FY2017 | Dec 31, 2016 | $3.0K | Mar 30, 2018 |
| FY2016 | Dec 31, 2015 | $34.0K | Mar 31, 2017 |
| FY2015 | Dec 31, 2014 | $309.0K | Mar 29, 2016 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $8.19M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $4.09M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $8.81M | Nov 26, 2025 |
| FY2023 | Dec 31, 2022 | $28.05M | Mar 21, 2024 |
| FY2022 | Sep 30, 2022 | $31.57M | Nov 29, 2023 |
| FY2022 | Jun 30, 2022 | $35.90M | Nov 29, 2023 |
| FY2022 | Mar 31, 2022 | $40.18M | Nov 29, 2023 |
| FY2022 | Dec 31, 2021 | $43.14M | Nov 29, 2023 |
| FY2022 | Sep 30, 2021 | $45.29M | Nov 29, 2023 |
| FY2021 | Dec 31, 2020 | $36.80M | Mar 30, 2022 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.34M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $6.27M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $8.20M | Nov 26, 2025 |
| FY2023 | Dec 31, 2022 | $7.62M | Mar 21, 2024 |
| FY2022 | Sep 30, 2022 | $4.58M | Nov 29, 2023 |
| FY2022 | Jun 30, 2022 | $5.26M | Nov 29, 2023 |
| FY2022 | Mar 31, 2022 | $6.34M | Nov 29, 2023 |
| FY2022 | Dec 31, 2021 | $5.44M | Nov 29, 2023 |
| FY2022 | Sep 30, 2021 | $3.70M | Nov 29, 2023 |
| FY2021 | Dec 31, 2020 | $3.54M | Mar 30, 2022 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.84M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($2.17M) | Mar 30, 2026 |
| FY2025 | Dec 31, 2023 | $607.0K | Mar 30, 2026 |
| FY2024 | Dec 31, 2022 | $15.94M | Nov 26, 2025 |
| FY2022 | Sep 30, 2022 | $22.50M | Nov 29, 2023 |
| FY2022 | Jun 30, 2022 | $29.53M | Nov 29, 2023 |
| FY2022 | Mar 31, 2022 | $33.84M | Nov 29, 2023 |
| FY2023 | Dec 31, 2021 | $37.69M | Mar 21, 2024 |
| FY2022 | Sep 30, 2021 | $41.59M | Nov 29, 2023 |
| FY2022 | Dec 31, 2020 | $33.26M | Nov 29, 2023 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.57M | Mar 30, 2026 |
| FY2025 | Sep 11, 2025 | $1.57B | Mar 30, 2026 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($454.41M) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($439.49M) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | ($428.28M) | Nov 26, 2025 |
| FY2023 | Dec 31, 2022 | ($405.73M) | Mar 21, 2024 |
| FY2022 | Sep 30, 2022 | ($398.31M) | Nov 29, 2023 |
| FY2022 | Mar 31, 2022 | ($388.64M) | Nov 29, 2023 |
| FY2022 | Dec 31, 2021 | ($384.53M) | Nov 29, 2023 |
| FY2022 | Sep 30, 2021 | ($379.43M) | Nov 29, 2023 |
| FY2021 | Dec 31, 2020 | ($366.07M) | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | ($357.63M) | Mar 1, 2021 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.51M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $3.14M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $3.38M | Nov 26, 2025 |
| FY2023 | Dec 31, 2022 | $18.35M | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | $36.56M | Nov 29, 2023 |
| FY2021 | Dec 31, 2020 | $33.41M | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | $11.89M | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | $17.50M | Mar 5, 2020 |
| FY2018 | Dec 31, 2017 | $23.91M | Mar 28, 2019 |
| FY2018 | Dec 31, 2016 | $16.52M | Mar 28, 2019 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (6) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | (502) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | (6,419) | Nov 26, 2025 |
| FY2022 | Dec 31, 2022 | (1) | Mar 8, 2023 |
| FY2022 | Dec 31, 2021 | (2) | Nov 29, 2023 |
| FY2022 | Sep 30, 2021 | 0 | Nov 29, 2023 |
| FY2021 | Dec 31, 2020 | (3) | Mar 30, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (6) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | (502) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | (6,419) | Nov 26, 2025 |
| FY2023 | Dec 31, 2022 | (27) | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | (2) | Nov 29, 2023 |
| FY2022 | Sep 30, 2021 | 0 | Nov 29, 2023 |
| FY2021 | Dec 31, 2020 | (3) | Mar 30, 2022 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 5.40M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | 36,913 | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | 4,412 | Nov 26, 2025 |
| FY2023 | Dec 31, 2022 | 628,139 | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | 9.99M | Nov 29, 2023 |
| FY2021 | Dec 31, 2020 | 6.25M | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | 859,998 | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | 12.50M | Mar 5, 2020 |
| FY2018 | Dec 31, 2017 | 12.00M | Mar 28, 2019 |
| FY2017 | Dec 31, 2016 | 4.26M | Mar 30, 2018 |